124.89

0.29% 0.36

After Hours: 124.89

Sarepta Therapeutics Inc (SRPT)

Overview News Price History Option Chain Financials Why SRPT Down? Discussions Forecast Stock Split

Sarepta Therapeutics Inc stock is traded at $124.89, with a volume of 668.79K. It is up +0.29% in the last 24 hours and down -8.02% over the past month. Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.

Previous Close:

$124.53

Open:

$124.93

24h Volume:

668.79K

Relative Volume:

0.67

Market Cap:

$11.85B

Revenue:

$1.50B

Net Income/Loss:

$47.30M

P/E Ratio:

-15.95

EPS:

-7.83

Net Cash Flow:

$-527.92M

1W Performance:

+0.08%

1M Performance:

-8.02%

6M Performance:

-3.53%

1Y Performance:

+3.03%

1-Day Range:

$123.68

$127.90

1-Week Range:

$123.27

$127.90

52-Week Range:

$55.25

$173.25

Sarepta Therapeutics Inc Stock (SRPT) Company Profile

Name

Sarepta Therapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

617-274-4000

Address

215 FIRST STREET, CAMBRIDGE, MA

Employee

1,314

Twitter

@sarepta

Next Earnings Date

2024-10-30

Latest SEC Filings

SRPT's Discussions on Twitter

Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-31-24	Initiated	BMO Capital Markets	Outperform
Dec-13-23	Resumed	Citigroup	Buy
Dec-12-23	Initiated	Deutsche Bank	Buy
Nov-21-23	Initiated	Wedbush	Outperform
Oct-31-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-31-23	Downgrade	Oppenheimer	Outperform → Perform
Jun-23-23	Downgrade	Evercore ISI	Outperform → In-line
Apr-26-23	Initiated	SMBC Nikko	Outperform
Apr-04-23	Initiated	Citigroup	Buy
Mar-01-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-22-22	Reiterated	BTIG Research	Buy
Dec-16-22	Upgrade	UBS	Neutral → Buy
Apr-04-22	Resumed	Cantor Fitzgerald	Overweight
Jan-05-22	Reiterated	Needham	Buy
Dec-09-21	Upgrade	Oppenheimer	Perform → Outperform
Nov-05-21	Upgrade	JP Morgan	Neutral → Overweight
Sep-15-21	Upgrade	Guggenheim	Neutral → Buy
Aug-05-21	Upgrade	JP Morgan	Underweight → Neutral
Jun-15-21	Initiated	BTIG Research	Buy
Apr-26-21	Resumed	Credit Suisse	Neutral
Jan-12-21	Downgrade	Citigroup	Buy → Neutral
Jan-11-21	Downgrade	UBS	Buy → Neutral
Jan-08-21	Downgrade	JP Morgan	Overweight → Underweight
Jan-08-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-08-21	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-11-20	Initiated	Berenberg	Hold
Oct-28-20	Initiated	UBS	Buy
Aug-25-20	Initiated	Raymond James	Outperform
Aug-20-20	Downgrade	Credit Suisse	Outperform → Neutral
Mar-31-20	Initiated	Mizuho	Buy
Nov-01-19	Initiated	Guggenheim	Buy
Aug-21-19	Reiterated	Needham	Buy
Jul-09-19	Reiterated	Morgan Stanley	Overweight
Jul-01-19	Reiterated	RBC Capital Mkts	Outperform
Apr-12-19	Initiated	Evercore ISI	Outperform
Mar-11-19	Reiterated	Credit Suisse	Outperform
Oct-12-18	Initiated	Bernstein	Outperform
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Sep-26-18	Reiterated	RBC Capital Mkts	Outperform
Sep-14-18	Resumed	BofA/Merrill	Buy
Sep-06-18	Initiated	Credit Suisse	Outperform
Aug-01-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-21-18	Reiterated	Robert W. Baird	Outperform
Jun-20-18	Reiterated	Needham	Buy
Jun-19-18	Reiterated	H.C. Wainwright	Buy

View All

Sarepta Therapeutics Inc Stock (SRPT) Latest News

04:39 AM

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

04:39 AM

12:39 PM

Is Sarepta Therapeutics, Inc. (SRPT) One of the Best Revenue Growth Stocks to Buy According to Analysts? - Insider Monkey

12:39 PM

12:38 PM

Is Sarepta Therapeutics, Inc. (SRPT) One of the Best Revenue Growth Stocks to Buy According to Analysts? - Yahoo Finance

12:38 PM

11:14 AM

Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher - sharewise

11:14 AM

09:43 AM

Sarepta Therapeutics' SWOT analysis: broad elevidys label boosts stock outlook - Investing.com

09:43 AM

Sep 29, 2024

7 Best Revenue Growth Stocks to Buy According to Analysts - Insider Monkey

Sep 29, 2024

Sep 27, 2024

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress - BioSpace

Sep 27, 2024

Dispute over Duchenne gene therapy highlights thorny access issues - STAT

Sep 27, 2024

Lighthouse Investment Partners LLC Invests $7.95 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Sep 27, 2024

Sep 26, 2024

The Play On Sarepta Therapeutics (NASDAQ:SRPT) - Seeking Alpha

Sep 26, 2024

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress - StockTitan

Sep 26, 2024

Duchenne Muscular Dystrophy Treatment Market Will Accelerate - openPR

Sep 26, 2024

Point72 Hong Kong Ltd Acquires New Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Sep 26, 2024

Sep 25, 2024

Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online

Sep 25, 2024

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Fred Alger Management LLC - MarketBeat

Sep 25, 2024

Sep 24, 2024

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Avoro Capital Advisors LLC - MarketBeat

Sep 24, 2024

Sep 23, 2024

Exploring TeraWulf And Two Other High Growth Tech Stocks - Simply Wall St

Sep 23, 2024

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Sep 23, 2024

Profund Advisors LLC Buys 17,132 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Sep 23, 2024

Sep 22, 2024

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Ensign Peak Advisors Inc - Defense World

Sep 22, 2024

Sep 21, 2024

Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options - MSN

Sep 21, 2024

Sarepta Therapeutics (SRPT): Soaring with Successful Therapies and Cash Flow Positivity - Yahoo Finance

Sep 21, 2024

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Forecasted to Post Q1 2026 Earnings of $2.75 Per Share - MarketBeat

Sep 21, 2024

Sep 20, 2024

Sarepta Therapeutics (NASDAQ:SRPT) Receives Neutral Rating from Cantor Fitzgerald - MarketBeat

Sep 20, 2024

Zacks Research Equities Analysts Boost Earnings Estimates for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Sep 20, 2024

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Simplify Asset Management Inc. - MarketBeat

Sep 20, 2024

Sarepta Therapeutics (NASDAQ:SRPT) Receives "Outperform" Rating from Royal Bank of Canada - MarketBeat

Sep 20, 2024

Marvell co-founder Sehat Sutardja has died as industry mourns semiconductor visionary - DIGITIMES

Sep 20, 2024

Sep 19, 2024

Blair William & Co. IL Has $27.54 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World

Sep 19, 2024

Sehat Sutardja, semiconductor pioneer and Marvell co-founder, has died - Berkeley Engineering

Sep 19, 2024

Sacha Feinberg-Mngomezulu is the future of the Springboks, but don’t write off Manie Libbok just yet - IOL

Sep 19, 2024

Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options - Yahoo Finance

Sep 19, 2024

Blair William & Co. IL Increases Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Sep 19, 2024

Sarepta Therapeutics (NASDAQ:SRPT) PT Raised to $188.00 at UBS Group - MarketBeat

Sep 18, 2024

Sofinnova Investments Inc. Decreases Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Sep 18, 2024

Sep 17, 2024

Investing in Sarepta Therapeutics (NASDAQ:SRPT) five years ago would have delivered you a 55% gain - Simply Wall St

Sep 17, 2024

Sep 16, 2024

Acadian Asset Management LLC Buys New Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Sep 16, 2024

Sarepta Therapeutics appoints new board member - Investing.com

Sep 16, 2024

Sarepta Therapeutics appoints new board member By Investing.com - Investing.com Canada

Sep 16, 2024

Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors - citybiz

Sep 16, 2024

Sarepta Therapeutics Expands Board, Welcomes New Director - TipRanks

Sep 16, 2024

Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors - Business Wire

Sep 16, 2024

Sep 15, 2024

Texas Permanent School Fund Corp Takes Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Sep 15, 2024

Sep 14, 2024